Search

everythinglearnresearchcommunity

for

Search:↓

Hair regrowth treatments for cis-males include Minoxidil, Finasteride, and RU58841. Estrogen and testosterone blockers can help restore hair loss but may not suit everyone.

Finasteride is discussed for hair loss treatment, with opinions divided on its safety and effectiveness. Some consider natural remedies, but these may also affect hormones.

Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.

The user reported early stage diffuse hair thinning and increased DHT levels after 4 weeks on Finasteride and 8 weeks on Finasteride plus 4 weeks on Dutasteride, despite the medications being authentic and stored properly. They are considering increasing their Dutasteride dosage due to the lack of side effects and are unsure if the treatment is helping their hair.

Finasteride can cause sexual side effects, and reducing porn and masturbation may help improve sexual function. Some users experience persistent issues even after stopping finasteride.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

A 21-year-old man shared his 2.5-year experience with hair loss treatments, including 1mg Propecia (finasteride) nightly, 12.5% Minoxidil once daily, 2% Nizoral shampoo 2-4 times a week, and later 5% Minoxidil once daily. He experienced minor side effects like watery semen and itchy scalp, and while he's seen fluctuations in hair growth, he's generally happy with the results and is considering experimental treatments like CB-03-01 and RU58841.

The post discusses using Carnitine Tartrate, Potassium Chloride, and Niacin to reduce hair shedding, with the user experiencing significant improvement. The user also suggests considering a ketogenic/paleo diet for those with insulin resistance-related hair loss.

The conversation discusses hair loss treatments, specifically Rogaine and Finasteride, with concerns about Finasteride's potential sexual side effects. Users share personal experiences, with some switching to Dutasteride for better results, and others reporting hair regrowth without side effects.

Using dutasteride 0.5mg three times a week may be more effective than daily finasteride for hair regrowth, but experiences vary, with some users reporting side effects like anxiety and mood swings. Others suggest combining finasteride with dutasteride initially, while some find topical minoxidil more tolerable.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

Finasteride, minoxidil, and dutasteride can slow hair loss but aren't effective for everyone, especially with aggressive hair loss. Wayne Rooney's case shows treatments and transplants may not prevent hair loss due to genetics.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

The user has been using dutasteride twice a week for 8 months and oral minoxidil for 3 months but is experiencing increased hair thinning. Many recommend taking dutasteride daily for improved results.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

The user experienced significant hair regrowth and thicker hair after 5 months of using oral Dutasteride and Minoxidil, with no side effects. They regret not starting the treatment sooner and encourage others to try it, noting the ease of obtaining prescriptions online.

Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.

Dutasteride caused persistent hair shedding and no improvement for 18 months, leading to a switch back to finasteride. The user also uses oral minoxidil and plans to focus on better scalp health.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

Hair loss affects confidence, with discussions on treatments like finasteride, minoxidil, and RU58841. Emphasis is placed on self-acceptance and building confidence beyond appearance.

Switching from finasteride to dutasteride caused significant shedding but minimal side effects. The user plans to continue dutasteride for 12 months despite concerns about hair density.

The user is experiencing significant hair loss after switching from finasteride to dutasteride for five months. Suggestions include that the hair loss might be a normal shedding phase, with some recommending continuing the treatment for up to 24 months or considering alternatives like RU58841.

A young person is distressed about rapid hair loss despite using finasteride and recently starting oral minoxidil. Many suggest continuing treatment, considering dutasteride, and seeking therapy for mental health support.